Determinants of Predicted Efficacy of Antiarrhythmic Drugs in the Electrophysiologic
Study Versus Electrocardiographic Monitoring Trial
The ESVEM Investigators
Background. The Electrophysiologic Study Versus Electrocardiographic Monitoring (ESVEM) study was designed to compare the accuracy of predictions of antiarrhythmic drug efficacy made by electrophysiological study (EPS) with those made by Holter monitoring (HM) combined with exercise testing. The present study describes the baseline characteristics and the response to drug efficacy tests of 486 randomized subjects.
Methods and Results. Patients with ventricular tachyarrhythmias were randomly assigned to undergo serial testing of up to six antiarrhythmic drugs by either EPS (EPS limb) or HM and exercise testing (HM limb) . Efficacy predictions were achieved in 108 of 242 patients in the EPS limb (45%) and in 188 of 244 patients (77%) in the HM limb. Left ventricular ejection fraction (LVEF) <0.25 and presence of coronary artery disease were negative correlates (p<0.10) of drug efficacy predictions in the EPS limb. In the HM limb, LVEF was the lone univariate correlate of efficacy, although it was only marginally significant (p=0.107). A multivariate model selected assessment by HM and higher LVEF as independent predictors (p<O.OS) of drug efficacy. The drug evaluation process required an actuarial median time of 25 days in the EPS limb and 10 days in the HM limb (p<0.0001).
Conclusions. 1) Drug efficacy predictions are achieved more frequently by HM than by EPS. 2) Assessment by HM and severity of left ventricular dysfunction are independent correlates of a drug efficacy prediction.
3) The duration of drug testing is considerably shorter for the HM method. (Circulation 1993; 87:323-329) KEY WORDs * electrophysiological study * Holter monitoring * tachyarrhythmia, ventricular sudden death E lectrophysiological studies (EPS)1 and ambulatory electrocardiographic (Holter) monitoring (HM) combined with exercise tests2 have been reported to identify antiarrhythmic drugs that prolong the time to arrhythmia recurrence in patients with sustained ventricular tachyarrhythmias. The probability of identifying an effective drug is influenced by a patient's clinical characteristics. [3] [4] [5] The Electrophysiologic Study Versus Electrocardiographic Monitoring (ESVEM) Trial was a multicenter, randomized clinical study that tested the hypothesis that one of these two testing methods is more accurate in identifying individual drugs that are associated with freedom from ventricular tachyarrhythmia recurrence in individual patients. 
Clinical Characteristics of Randomized Patients
The mean age of randomized patients was 65 years (see Table 1 ). The great majority of patients were men with CAD and previous MI, and three fourths presented with sustained VT. Two thirds had previously failed at least one antiarrhythmic drug trial. Most had a mean PVC frequency greater than 30/hr and inducible sustained VT. Three fourths had symptomatic congestive heart failure. The mean LVEF was 0.32. There were no statistically or clinically significant differences in patients randomized to the two limbs except for p8-blocker use (10% in the EPS limb versus 17% in the HM limb, p=0.022).
Prediction of Efficacy
Frequency of efficacy predictions was calculated on the basis of individual drug trials ( Figure 2 ) and on the basis of individual patients (Figure 3 ). There were 1,281 individual antiarrhythmic drug trials (an average of 2.6 trials per patient). The There were 296 among the 486 patients who were randomized (61%) in whom antiarrhythmic drug efficacy was predicted. In nine patients, efficacy was predicted for two drugs. The second efficacy prediction resulted from a second series of drug testing that was permitted in patients in whom the first drug that was predicted to be effective had to be discontinued because of side effects within 1 month. One patient received three efficacy predictions. The first drug was discontinued because it was mistakenly thought to be ineffective, and the second was discontinued because of side effects after hospital discharge. No 
Time Required for Testing
Among patients who achieved a drug efficacy prediction, the time required was nearly identical (p=0.27) in the two limbs ( Figure 4, left panel) ; the actuarial median time to an efficacy prediction from the day of randomization was 9 days in the EPS limb and 8 days in the HM limb. The duration of testing among all patients, including those in whom no drug was predicted effective, was longer (p=0.0001) in the EPS limb (Figure 4, right panel) Weeks After Randomization Some univariate correlates of efficacy predictions appeared to differ in the two limbs, but multivariate analysis did not support meaningful interactions with the limb. LVEF was the only clinical variable that exerted a significant influence on the likelihood of an efficacy prediction, and this effect was the same in both limbs.
Three previous studies have identified clinical correlates of a drug efficacy prediction by EPS testing.
Among the variables that we tested, Swerdlow and colleagues3 identified coronary disease, previous antiarrhythmic drug inefficacy, and male sex to be statistically significant negative univariate correlates of an efficacy prediction. We also found coronary disease to be significant and identified a trend for sex in the EPS limb but in the univariate model only. They did not evaluate LVEF but did find heart failure classification to be predictive. We found LVEF predictive rather than heart failure class. Schoenfeld and associates4 performed a similar analysis. They found only previous antiarrhythmic drug failure to be an independent predictor among the variables we examined. The nature of the induced ventricular tachyarrhythmia was also a predictor in their multivariate model. However, their study included a larger proportion of subjects resuscitated from out-ofhospital cardiac arrest than Swerdlow and colleagues' or ours as well as patients with unsustained VT. Spielman et al5 identified older age, lower ejection fraction, left ventricular aneurysm, and presence of coronary disease to be independent predictors of drug efficacy by EPS testing in a patient population similar to ours. We did not examine aneurysm as a predictor in our study.
Male sex was found to be a negative correlate of efficacy predictions in the study of Swerdlow et al.3 Freedman et a119 found male sex to be the strongest independent predictor of ventricular arrhythmia inducibility in survivors of cardiac arrest, and inducibility was the strongest predictor of a poor long-term outcome. 20 We also found that female sex favored a response at EPS compared with HM, but the interaction was weak, and sex did not predict outcome in our multivariate model. There is no immediately apparent reason why women seem to fare better then men with ventricular tachyarrhythmias undergoing serial drug testing by EPS. Underlying disease could play a role in that existing measures of coronary disease may not be sufficiently sensitive and precise to establish the true extent of correlation between sex and disease. by guest on September 16, 2017 http://circ.ahajournals.org/
Downloaded from
Drug selection by the EPS method required more time in comparison with the HM method. This difference was primarily a result of protracted testing in the EPS limb in patients who ultimately were unresponsive to most or all of the drugs. Although this observation might suggest that the duration of testing by EPS should be limited, we observed that testing extended beyond 23 days was nearly three times as likely to yield an efficacy prediction in the EPS limb compared with the HM limb. Nevertheless, a longer period of hospitalization increases cost and exposes the patient to potential adverse effects of additional antiarrhythmic drugs. This analysis shows that HM produces more predictions of antiarrhythmic drug efficacy than EPS. However, this finding alone does not indicate superiority of the HM testing method for identification of antiarrhythmic drug efficacy in patients with ventricular tachyarrhythmias. The accuracy of predictions by EPS and HM will be the principal determinant of their relative clinical use.
